Literature DB >> 17957097

Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.

Mario Traut1, Christoph C Haufe, Ulrike Eismann, Reinhold M Deppisch, Gunter Stein, Gunter Wolf.   

Abstract

BACKGROUND: Patients on long-term dialysis eventually develop amyloid deposits with beta2-microglobulin as a predominant component. Although several studies have suggested that high-flux membranes reduce beta2-microglobulin in plasma compared with low-flux dialyzers, the mechanisms underlying this observation are still discussed.
METHODS: We revisited this important subject and measured beta2-microglobulin in the plasma of healthy individuals (n = 8), and patients undergoing hemodialysis (n = 20) who for assigned periods of time were either treated with a low-flux membrane (cuprophan) or high-flux (polyamide) dialyzer with an ELISA. The number of blood cells was determined by FACS. Beta2-microglobulin was also measured on the surface of granulocytes, lymphocytes, and monocytes before, directly after, and 4 h after hemodialysis. Expression of beta2-microglobulin, c-fos, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 mRNA was determined in whole blood samples with quantitative RT-PCR using an internal standard in parallel. In the second part of the study, patients were assigned in a two-group cross-over design either to low- or high-flux dialyzers (n = 9 in each group), and dialyzer membranes were changed every 4 weeks for two consecutive periods. Serum beta2-microglobulin concentrations were measured at the end of each period.
RESULTS: Healthy controls had a low plasma beta2-microglobulin level of 1.2 +/- 0.3 mg/l. Before hemodialysis, patients on low-flux dialyzers had a plasma beta2-microglobulin level of 42.0 +/- 14.0 mg/l, patients treated with high-flux dialyzers 21.5 +/- 10.8 mg/l (p < 0.05 vs. low-flux dialyzers). In contrast, there was no significant difference in plasma concentrations of active transforming growth factor-beta1 with the two different membrane types. The difference in serum beta2-microglobulin between low- and high-flux membranes was more prominent directly after hemodialysis as well as 4 h after hemodialysis compared with the values directly before the start of treatment. At all studied time-points, leukocytes and platelets were significantly higher in patients on low-flux membranes. Healthy control persons exhibited a significantly higher amount of beta2-microglobulin bound to granulocytes, lymphocytes, and monocytes compared with dialysis patients. Interestingly, beta2-microglobulin bound to granulocytes, lymphocytes, and monocytes was significantly increased in patients treated with high-flux membranes compared with low-flux filters. Quantitative RT-PCR revealed no significant difference in beta2-microglobulin expression in whole blood before hemodialysis, directly after hemodialysis, and 4 h after hemodialysis. However, TNF-alpha and c-fos transcripts were significantly higher in whole blood obtained from patients treated with low-flux membranes compared to high-flux dialyzers. The two-group cross-over study over three periods of 4 weeks revealed that switching from low-flux to high-flux dialyzers significantly reduced serum beta2-microglobulin levels.
CONCLUSION: Patients treated with a polyamide high-flux membrane had lower beta2-microglobulin concentrations compared with those patients on low-flux dialyzers. This difference might not be mediated by an increase in beta2-microglobulin mRNA, but may be caused by less beta2-microglobulin released from the blood cells in patients treated with high-flux dialyzers, in addition to a better beta2-microglobulin clearance. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17957097     DOI: 10.1159/000110069

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

2.  Strategy for degradomic-peptidomic analysis of human blood plasma.

Authors:  Yufeng Shen; Tao Liu; Nikola Tolić; Brianne O Petritis; Rui Zhao; Ronald J Moore; Samuel O Purvine; David G Camp; Richard D Smith
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 3.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

4.  Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry.

Authors:  Masanori Abe; Takayuki Hamano; Atsushi Wada; Shigeru Nakai; Ikuto Masakane
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

Review 5.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

6.  The unresolved problem of beta-2 microglobulin amyloid deposits in the intervertebral discs of long-term dialysis patients.

Authors:  Tsung-Ting Tsai; Arun-Kumar Kaliya-Perumal; Chang-Chyi Jenq; Chi-Chien Niu; Natalie Yi-Ju Ho; Tung-Ying Lee; Po-Liang Lai
Journal:  J Orthop Surg Res       Date:  2017-12-21       Impact factor: 2.359

7.  Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

Authors:  Laura E Donovan; Eric B Dammer; Duc M Duong; John J Hanfelt; Allan I Levey; Nicholas T Seyfried; James J Lah
Journal:  Alzheimers Res Ther       Date:  2013-06-13       Impact factor: 6.982

8.  Measuring serum beta2-microglobulin to predict long-term mortality in hemodialysis patients using low-flux dialyzer reuse.

Authors:  Nguyen Huu Dung; Nguyen Trung Kien; Nguyen Thi Thu Hai; Phan The Cuong; Nguyen Thi Thu Huong; Dao Bui Quy Quyen; Nguyen Minh Tuan; Do Manh Ha; Truong Quy Kien; Nguyen Thi Thuy Dung; Pham Quoc Toan; Hoang Trung Vinh; Tomoko Usui; Le Viet Thang
Journal:  Ther Clin Risk Manag       Date:  2019-07-09       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.